A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis

Nature Protocols

Volumn 5, Issue 6, 2010, Pages 1107-1114

  Didone, Louis ^a   Scrimale, Thomas ^a   Baxter, Bonnie K ^a   Krysan, Damian J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ANTIFUNGAL AGENT;

ARTICLE; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; CYTOLOGY; DRUG DEVELOPMENT; DRUG EFFECT; ENZYMOLOGY; GENETIC PROCEDURES; GENETICS; HUMAN; IN VITRO STUDY; INSTRUMENTATION; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; SACCHAROMYCES CEREVISIAE; YEAST;

ADENYLATE KINASE; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; DRUG DISCOVERY; GENETIC TECHNIQUES; HUMANS; MICROBIAL SENSITIVITY TESTS; SACCHAROMYCES CEREVISIAE; YEASTS;

EID: 77956678680     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2010.47     Document Type: Article

References (15)

1. Patterson, T.F., Advances and challenges in management of invasive mycoses. Lancet 366, 1013-1025 (2006).
2. Shorr, A.F., Gupta, V., Sun, X., Johannes, R.S., Spalding, J., Tabak, Y.P., Burden of early-onset candidemia: Analysis of culture-positive bloodstream infections from a large US database. Crit. Care Med. 37, 2519-2526 (2009).
3. Spanakis, E.K., Aperis, G., Mylonakis, E., New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 43, 1060-1068 (2006).
4. Nucci, M., Perfect, J.R., When primary antifungal therapy fails. Clin. Infect. Dis. 46, 1426-1433 (2008).
5. Wilson, L.C., Reyes, C.M., Stolpman, M., Speckman, J., Allen, K., Beney, J., The direct cost of systemic fungal infections. Value Health 5, 26-34 (2002).
6. Payne, D.J., Gwynn, M.N., Dolmes, D.J., Pompliano, D.L., Drugs for bad bugs: confronting challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
7. Tampakakis, E., Okoli, I., Mylonakis, E.A. C., Elegans-based, whole animal in vivoscreen for the identification of antifungal compounds. Nat. Protoc. 3, 1925-1931 (2008).
8. Pierce, C.G., Uppuluri, P., Tristan, A.R., Wormley, F.L. Jr., Mowat, E., Lopez-Ribot, J.L., A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3, 1494-1500 (2008).
9. Krysan, D.J., DiDone, L. A, High-throughput screening assay for small molecules that disrupt yeast cell integrity. J. Biomol. Screen 13, 657-664 (2008).
10. Cannon-Clarke, A., Hulse, G.A., Clifton, L., Cantrell, I.C., The use of adenylate kinase measurement to determine the causes of lysis in lager yeast. J. Am. Soc. Brew. Chem. 61, 152-156 (2003).
11. Cabib, E., Blanco, N., Grau, C., Rodriguez-Pena, J., Arroyo, J., Crh1p and Crh2p are required for the cross-linking of chitin to β(1, 6)-glucan in the Saccharomyces cerevisiaecell wall. Mol. Microbiol. 63, 921-935 (2007).
12. Graybill, J.R., Burgess, D.S., Hardin, T.C., Key issues concerning fungistatic versus fungicidal drugs. Eur. J. Clin. Microbiol. Infect. Dis. 16, 42-50 (1997).
13. Sloan, D.J., Dedicoat, M.J., Lallo, D.G., Treatment of cryptococcal meningitis in resource limited settings. Curr. Opin. Infect. Dis. 22, 455-463 (2009).
14. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard M27-a2(National Committee for Clinical Laboratory Standards. Wayne, PA, 2002).
15. Bruno, V.M., Kalachikov, S., Subaran, R., Nobile, C.J., Kyratsous, C., Mitchell, A.P., Control of the C. albicanscell wall damage response by transcriptional regulator Cas5. PLOS Pathog. 2, e21 (2006).